Eli Lilly and Company and Merck KGaA’s Erbitux May Help Some Cancer Patients With Mutation, Study Finds

Bloomberg -- Eli Lilly & Co. and Merck KGaA’s Erbitux helped a group of cancer patients thought to be immune to the treatment in a study that contradicts earlier assumptions of the way the drug works in those with a genetic mutation.